MeiraGTx Holdings plc Shareholders' Equity
MeiraGTx Holdings plc (MGTX) had Shareholders' Equity of -$58.13 million as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-05-14
- 2026-03-31: Stockholders' Equity Attributable to Parent -$58.13M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$5.79M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$40.56M.
- 2025-06-30: Stockholders' Equity Attributable to Parent $2.96M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-03-31 | -$58.13M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$5.79M 10-Q · filed 2026-05-14 | |
| 2025-09-30 | -$40.56M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $2.96M 10-Q · filed 2025-11-13 | |
| 2025-03-31 | $33.10M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $67.83M 10-Q · filed 2026-05-14 | |
| 2024-09-30 | $95.74M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $80.04M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $121.73M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $138.18M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $91.89M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $123.53M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $90.22M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $117.74M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $122.67M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $141.97M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $161.28M 10-Q · filed 2023-11-14 | $161.28M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $185.40M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $187.84M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $205.72M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $220.79M 10-Q · filed 2022-11-10 | $220.79M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $238.56M 10-K · filed 2023-03-14 | $238.56M 10-K · filed 2021-03-11 |
| 2020-09-30 | $179.09M 10-Q · filed 2021-11-10 | $179.09M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $172.77M 10-Q · filed 2021-11-10 | $172.77M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $184.93M 10-Q · filed 2021-11-10 | $184.92M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $190.80M 10-K · filed 2022-03-10 | $190.80M 10-K · filed 2020-03-11 |
| 2019-09-30 | $194.89M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $129.56M 10-Q · filed 2020-11-05 | $129.56M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $144.42M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $81.06M 10-K · filed 2021-03-11 | |
| 2018-09-30 | $96.34M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $108.47M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | -$60.92M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | -$47.37M 10-K · filed 2020-03-11 | |
| 2016-12-31 | -$17.14M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |